Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil

Vaccine

Volumn 30, Issue 32, 2012, Pages 4892-4896

  Mahoney, R T ^a   Francis, D P ^b   Frazatti Gallina, N M ^c   Precioso, A R ^c   Raw, I ^c   Watler, P ^d   Whitehead, P ^e   Whitehead, S S ^f  

^a International Vaccine Institute   (South Korea)

^b Global Solutions for Infectious Diseases   (United States)

^c INSTITUTO BUTANTAN   (Brazil)

^d Hyde Engineering + Consulting   (United States)

^e Neovacs SA   (France)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cost of production; Dengue; Vaccine

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

ARTICLE; BRAZIL; DENGUE; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; ECONOMIC ASPECT; HEALTH CARE PERSONNEL; HUMAN; LABOR; LICENSING; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL;

BRAZIL; COSTS AND COST ANALYSIS; DENGUE; DENGUE VACCINES; DRUG COSTS; DRUG INDUSTRY; HUMANS; VACCINES, ATTENUATED;

EID: 84862577226     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.064     Document Type: Article

References (13)

1. Beatty M.E., Letson G.W., Margolis H.S. Estimating the Global Burden of Dengue. Second International Conference of Dengue and Dengue Haemorrhagic Fever 2008.
2. Herrling P. Experiments in social responsibility. Nature 2006, 439(7074):267-268.
3. Teixeira M.G., Costa M.C., Barreto M.L., Mota E. Dengue and dengue hemorrhagic fever in epidemics in Brazil: what research is needed based on trends, surveillance, and control experiences?. Cad Saude Publica de Janeiro 2005, 21(5):1307-1315.
4. Halstead S.B. Dengue Lancet 2007, 370(9599):1644-1652.
5. Burke D.S., Nisalak A., Johnson D.E., Scott R.M. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988, 38(1):172-180.
6. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181(1):2-9.
7. Gibbons R.V., Kalanarooj S., Jarman R.G., Nisalak A., Vaughn D.W., Endy T.P., et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007, 77(5):910-913.
8. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587-619.
9. Amarasinghe A., Mahoney R.T. Estimating potential demand and supply of dengue vaccine in Brazil. Hum Vaccin 2011, 7(7):776-780.
10. Amarasinghe A., Wichmann O., Margolis H.S., Mahoney R.T. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum Vaccin 2010, 6(9):745-753.
11. Whitehead P, Pasternak A. Lesson Learned: New Procurement Strategies for Vaccines. Final Report to the GAVI Board; 2002 [cited 2009 January 8]; available from: http://www.gavialliance.org/resources/Mercer_lessons_draft_final.pdf.
12. Mahoney R.T. Cost of plasma-derived hepatitis B vaccine production. Vaccine 1990, 8(4):397-401.
13. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30(6):1049-1057.